Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Eli Lilly logo
Eli LillyLLY
31.6×-6.7×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.2×+2.5×
Amgen logo
AmgenAMGN
16.7×-3.4×
AbbVie logo
AbbVieABBV
261×+221×
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
5.3×-0.8×

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=5×

Based on the most recent quarter.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769

FAQ

What is Oruka Therapeutics, Inc.'s price / book?
Oruka Therapeutics, Inc. (ORKA) reported price / book of 5× in Q1 2026.
How has Oruka Therapeutics, Inc.'s price / book changed year-over-year?
Oruka Therapeutics, Inc.'s price / book increased by 374.1% year-over-year, from 1.1× to 5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Oruka Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude